Business News

Haisco Medicine Group recently received the "Approval Notice for Drug Clinical Trials" issued by the National Medical Products Administration, allowing the clinical trial of HSK47388 Tablet (I) to be conducted in June 2026.

Source of image: Drug Evaluation Center of the National Medical Products Administration

HSK47388 tablet (I) is a oral, potent, highly selective drug independently developed by Haixike. Previously, this product has obtained clinical trial approvals for indications such as psoriasis and inflammatory bowel disease (UC/CD). The approval of the clinical trial application for psoriasis arthritis indication will further expand Haixike's product portfolio and offer new options for patients with a wider range of autoimmune diseases.

About Haisco

Hisicor is an international pharmaceutical company integrating research and development, production, and sales (stock code 002653.SZ). It focuses on areas such as anesthesia and analgesia, chronic disease metabolism, digestive liver diseases, respiratory autoimmune diseases, the nervous system, and tumors. Adhering to innovation and globalization strategies, with the vision of “becoming the most trusted international pharmaceutical company,” Hisicor aims to meet unmet clinical needs and care for patients worldwide. Currently, Hisicor Pharmaceutical Group has established a range of diversified research and development programs with independent intellectual property rights, covering small molecule innovative drugs, biopharmaceuticals, and high-end generic drugs. Many projects are in the clinical development stage, and several innovative drugs have been commercialized, providing diverse innovative product solutions to the world.

Statement

This information is intended to provide cutting-edge medical insights and research progress. It is for reference only by healthcare professionals, and is not intended for product promotion or advertising purposes. The content cannot replace professional medical guidance, and should not be considered as medical advice. Healthcare professionals should strictly follow the latest detailed prescribing information when prescribing any medications mentioned in this document.

Some content may include forward-looking statements. These statements are based on the company’s current expectations for future developments and may be influenced by various uncertain factors such as research and development progress, regulatory approvals, and market conditions. For specific statements, please visit: https://www.haisco.com/statement.html.